On December 4, Glonhu reported that Novavax Pharmaceuticals sold its production facility in the Czech Republic to Novo Nordisk for $0.2 billion. According to a statement released on Wednesday, Novavax Pharmaceuticals will transfer a 0.15 million square foot recombinant protein manufacturing facility and associated buildings to Novo Nordisk, along with the existing workforce and all relevant and necessary infrastructure. In addition to the $0.19 billion cash payment in 2024 and an additional $10 million in 2025, Novavax Pharmaceuticals expects the sale of the facility to reduce annual operating costs by approximately $80 million. President and CEO of Novavax Pharmaceuticals, John C. Jacobs, stated: 'The decision to sell the Czech manufacturing plant aligns with our previously announced commitment to develop Novavax Pharmaceuticals into a leaner and more agile organization, focusing on our pipeline assets and technology platform.'